Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition
Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications. Continue Reading
Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It’s Moving Beyond GLP-1s.
The company’s experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration. Continue Reading
The Midterms Are Coming. Tech Stocks May Have a Problem.
The vote is likely a “non-event for S&P 500 fundamentals” but could slow down the AI trade, equity strategist Scott Chronert said. Continue Reading
Personal imports of cheaper prescription drugs will soon get trickier
[Different Sizes of Empty Prescription Bottles stock photo] FatCamera/E+ via Getty Images Millions of Americans use mail-order pharmacies from Canada and other countries to personally import medication for a fraction of the U.S. cost. That…
Made in America again? That'll be $6.5T, please
[AI powers big data analysis and automation workflows, showcasing neural networks and data streams for business. Artificial intelligence, machine learning, digital transformation and tech innovation.] NicoElNino Restoring the U.S.'s eroded…
Why One of the Last Eli Lilly Holdouts Just Upgraded the Stock to Buy
Berenburg upgrades Eli Lilly stock to Buy from Hold, citing growth prospects fueled by its weight-loss drugs. Continue Reading
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market. While an excellent vehicle fo…
Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated, low-beta pharmaceutical exposure, while Invesco S&P 500 Equal Weight Health Care ETF (NYSEMKT:RSPH) provides equal-weighted access to the broader healthcare sector at…
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?
The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides a broad basket covering medical providers, devices, and biotechnology, while iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated exposure strictly to the drug manufactur…
SA Asks: What are the most promising oncology companies right now?
[Patients Receiving Medical Infusions in a Clinical Setting with Nurse Assistance] FatCamera/iStock via Getty Images Earlier this week, shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and partner Merck (MRK [https://seeking…
SA Asks: How could Trump's new executive order impact vaccine makers?
[Merck & Co. headquarters in Silicon Valley] Sundry Photography/iStock Editorial via Getty Images Earlier this month, President Donald Trump announced an executive order aimed at changing the number and timing of vaccines recommended for c…
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers a lower-cost entry into diversified pharmaceutical leaders, while the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets high-growth biotech and genetic engineering firms. Bot…
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and VanEck Biotech ETF (NASDAQ:BBH) offer targeted exposure to healthcare, with one focusing on established pharmaceutical giants and the other on high-growth genetic research firms. Both…
Moderna's 177% Surge Powers a Broad Biotech Rally
Biotechnology Moderna's eye-popping surge on Wednesday didn't just reward holders of the stock. It supercharged what was already one of the strongest corners of the market this year: biotech and pharma. Moderna and Merck said their persona…
Healthcare ETFs Are Looking Up: Here's Why
Healthcare ETFs are hitting one-year highs because the sector is benefiting from a solid combination of improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI/tech trades into defensive growth.…
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's…
SA Asks: What's the outlook for Big Pharma M&A?
[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [ht…
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. St…
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad healthcare exposure at a lower cost, while the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers a concentrated bet on U.S. drugmakers. While both funds t…
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Medtech giant Johnson & Johnson JNJ reported better-than-expected second-quarter 2026 results, surpassing Wall Street estimates on both the top and bottom lines. The quarterly performance was primarily driven by strong growth in the immuno…
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?
Vanguard Health Care ETF (NYSEMKT:VHT) provides broad-based sector coverage with a significantly lower expense ratio, while iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated access to domestic drug companies. Both ETFs pro…
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
Comparing the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the VanEck Biotech ETF (NASDAQ:BBH) reveals two distinct fund profiles. IHE tracks established, blue chip pharmaceutical companies, while BBH zeroes in on the research-intens…
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
Key Points IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE. Over the past five years, IHE has shown lower price volatility and experienced a much smalle…
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
Investors comparing the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the iShares Global Healthcare ETF (NYSEMKT:IXJ) must choose between concentrated U.S. pharmaceutical industry exposure and a broader, global healthcare strategy. Bo…
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
Key Points iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its…
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q2
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The Health Care Select Sector SPDR® Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]), which tracks the health car…
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
Key Points The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much st…
Noteworthy ETF Inflows: IHE, VTRS, RPRX, ZTS
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares US Pharmaceuticals ETF (Symbol: IHE) where we have detected an approximate $281.7 million dollar infl…
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006. Retail and institutional…
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
Johnson & Johnson JNJ, a healthcare behemoth with a market cap exceeding $600 billion and a portfolio spanning pharmaceuticals and medical devices, has delivered a stellar year-to-date surge of approximately 24.5%. This performance notably…
Tuesday's ETF Movers: IHE, PSI
In trading on Tuesday, the iShares US Pharmaceuticals ETF is outperforming other ETFs, up about 3.1% on the day. Components of that ETF showing particular strength include shares of Crinetics Pharmaceuticals, up about 98.8% and shares of T…
The Math Shows IHE Can Go To $110
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector's biggest players. Investors seeking p…
Small-cap stocks enjoy their best first half in 35 years. Here's what's driving it
Small-cap U.S. stocks are capping off one of their strongest first halves in decades. But this is not your ordinary small-cap boom led by traditional businesses linked to the economic cycle. This run, like the one going on with their large…
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005. While an excellent vehicle for long te…